Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Cipla
Mallinckrodt
UBS
Healthtrust
Harvard Business School
Express Scripts
Argus Health
Accenture
Daiichi Sankyo

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,592,450

« Back to Dashboard

Which drugs does patent 8,592,450 protect, and when does it expire?

Patent 8,592,450 protects XIIDRA and is included in one NDA.

This patent has twenty-one patent family members in fifteen countries.
Summary for Patent: 8,592,450
Title:Compositions and methods for treatment of eye disorders
Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Inventor(s): Gadek; Thomas (Oakland, CA), Burnier; John (Pacifica, CA)
Assignee: SARcode Bioscience Inc. (Brisbane, CA)
Application Number:13/398,542
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Device; Formulation; Delivery;

Drugs Protected by US Patent 8,592,450

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,592,450

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,045,457 Compositions and methods for treatment ➤ Subscribe
8,084,047 Compositions and methods for treatment of eye disorders ➤ Subscribe
8,168,655 Compositions and methods for treatment of eye disorders ➤ Subscribe
9,045,458 Compositions and methods for treatment ➤ Subscribe
8,771,715 Compositions and methods for treatment ➤ Subscribe
8,758,776 Compositions and methods for treatment ➤ Subscribe
9,051,297 Compositions and methods for treatment ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,592,450

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2444079 ➤ Subscribe
Slovenia 1881823 ➤ Subscribe
Portugal 2444079 ➤ Subscribe
Portugal 1881823 ➤ Subscribe
Poland 2444079 ➤ Subscribe
Lithuania 2444079 ➤ Subscribe
Japan 2017141297 ➤ Subscribe
Japan 2015187165 ➤ Subscribe
Japan 2013006880 ➤ Subscribe
Japan 2012107057 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cipla
Accenture
Argus Health
Medtronic
Cantor Fitzgerald
Citi
Fish and Richardson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot